iPSCs as a screening tool to predict risk of nonalcoholic fatty liver disease
Grant Award Details
Grant Type:
Grant Number:
DISC2-12358
Investigator(s):
Disease Focus:
Human Stem Cell Use:
Award Value:
$813,000
Status:
Closed
Progress Reports
Reporting Period:
Year 2 plus NCE
Grant Application Details
Application Title:
iPSCs as a screening tool to predict risk of nonalcoholic fatty liver disease
Public Abstract:
Research Objective
The objective of this proposal is to established undifferentiated iPSCs as a diagnostic tool for the prediction of nonalcoholic fatty liver disease onset and severity.
Impact
Despite the widespread estimated prevalence of NAFLD, there are currently no tools available to predict likelihood of NAFLD susceptibility beyond standard clinical and demographic information.
Major Proposed Activities
The objective of this proposal is to established undifferentiated iPSCs as a diagnostic tool for the prediction of nonalcoholic fatty liver disease onset and severity.
Impact
Despite the widespread estimated prevalence of NAFLD, there are currently no tools available to predict likelihood of NAFLD susceptibility beyond standard clinical and demographic information.
Major Proposed Activities
- Create an iPSC-based NAFLD risk score (iPSC-RS) by defining threshold values for oleate-induced intracellular lipid accumulation that distinguish iPSCs from NAFLD patients versus healthy controls.
- Validate the iPSC-RS in an independent set of iPSCs from 25 NAFLD cases and 25 healthy controls, and evaluate the it's reproducibility across biological replicates and independent laboratories.
- Compare the validated iPSC-RS to other NAFLD risk predictors based on genomic information alone.
Statement of Benefit to California:
Nonalcoholic fatty liver disease (NAFLD) is a widely undiagnosed condition, and is estimated to impact up to 30% of adults. NAFLD is most prevalent in Hispanics, with the absolute highest levels found in individuals of Mexican ancestry, and thus is relevant to California's LatinX population. As NAFLD is anticipated to become the leading cause of liver transplant, identifying Californians most at risk could address significant gaps in screening and prevention for this serious disease.
Publications
- Cell Mol Gastroenterol Hepatol (2022): Undifferentiated Induced Pluripotent Stem Cells as a Genetic Model for Nonalcoholic Fatty Liver Disease. (PubMed: 35863744)